Start Submission


Focus and Scope

European Journal of Molecular & Clinical Medicine (EJMCM) is the official publication of the European Society for Translational Medicine. EJMCM publishes high quality manuscripts covering all aspects of molecular and clinical medicine. Submitted manuscripts are peer reviewed and selection is based on scientific excellence, distinctive contribution to knowledge and importance to the field. To provide a single platform for immediate dissemination of latest discoveries & developments from benchside and bedside, EUSTM has merged both of the Society’s journals; ‘New Horizons in Translational Medicine’ and ‘New Horizons in Clinical Case Reports’ into one publication: European Journal of Molecular & Clinical Medicine (EJMCM)

Molecular Medicine Section: Special consideration will be given to novel findings generated in cellular and molecular biology, genetics, stem cell biology, microbiology, immunology and the omics disciplines. In addition, quality manuscripts describing novel developments in the field of biomarkers, disease modelling, large data set mining will be considered for publication.

Clinical Medicine Section: Special consideration will be given to high quality clinical studies and case reports from all clinical specialties. Manuscripts should provide new insight and contribute to advance medical knowledge. 

Publication Frequency

The journal is published online as a continuous volume and issue throughout the year. Articles are made available as soon as they are ready to ensure that there are no unnecessary delays in getting content publically available.

Special collections of articles are welcomed and will be published as part of the normal issue, but also within a separate collection page.

Open Access Policy

This journal operates at a Gold Standard level of open access. It provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. It complies with open access funding body policies and also encourages the publication of research data.

Authors of articles published remain the copyright holders and grant third parties the right to use, reproduce, and share the article according to the Creative Commons license agreement.

Archiving Policy

The journal’s publisher focuses on making content discoverable and accessible through indexing services. Content is also archived around the world to ensure long-term availability.

Journals are indexed by the following services:

CrossRef, JISC KB+, SHERPA RoMEO, Directory of Open Access Journals (DOAJ), and Google Scholar. In addition, all journals are available for harvesting via OAI-PMH.

To ensure permanency of all publications, this journal also utilises CLOCKSS, and LOCKSS archiving systems to create permanent archives for the purposes of preservation and restoration.

Articles that are NIH funded require the author to deposit the details in pubmed. Information on how to do this can be found here.

If the journal is not indexed by your preferred service, please contact us or alternatively by making an indexing request directly with the service.

Advertisement policy

The journal only displays advertisements that are of relevance to its scope and will be of interest to the readership (e.g. upcoming conferences). All advertising space is provided free of charge and the editor and publisher have the right to decline or withdraw adverts at any point. Advertisement in the Journal does not constitute on the part of the Publisher or the Society (EUSTM) a guarantee or endorsement of the quality or value of the advertised products or services described therein or of any of the representations or the claims made by the advertisers with respect to such products or services.

If you wish to propose a potential advert then please contact the editorial team. All advert images will have to be provided to the publisher.


No responsibility is assumed by the Publisher nor by the Society (EUSTM) for any injury and/or damage to persons or property as a result of any actual or alleged libellous statements, infringement of intellectual property or privacy rights, or products liability.

Quick links